Research shows how 'Mallard' dye fills need for speedFebruary 15, 2013
Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood.
Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.
In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.
The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.
Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.
Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.
"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."
The York researchers worked with a team led by Sabrina Pricl at the University of Trieste who used high-level computer modelling to understand precisely how Mallard Blue binds to heparin so strongly.
The next stage in this research would involve the incorporation of this new dye into a device for simple bedside read-out of heparin levels in blood.
University of York
Related Heparin Current Events and Heparin News Articles
Apixaban in deep vein thrombosis and pulmonary embolism: patients with high BMI benefit considerably
Apixaban (trade name Eliquis) has been approved since July 2014 for acute treatment of adults with deep vein thrombosis or pulmonary embolism.
Combined strategies help patients with adverse heparin reaction before heart surgery
New evidence suggests that therapeutic plasma exchange and appropriate blood testing could help patients who are in urgent need of heart surgery, but have a history of an adverse reaction to the blood thinner heparin.
Some heparin-allergic patients could have urgent heart surgery sooner with combination of appropriate blood screenings and therapeutic plasma exchange
McMaster University researchers have found new evidence that suggests patients with a history of adverse reaction to the blood thinner heparin may be ready for urgent heart surgery sooner with a combination of appropriate blood screenings and therapeutic plasma exchange.
UBC researchers aim to simplify life saving drug
Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by developing a universal antidote.
Were clinical trial practices in East Germany questionable?
Clinical trials carried out in the former East Germany in the second half of the 20th century were not always with the full knowledge or understanding of participants with some questionable practices taking place, according to a paper published online in the Journal of Medical Ethics.
Bioinspired coating for medical devices repels blood and bacteria
From joint replacements to cardiac implants and dialysis machines, medical devices enhance or save lives on a daily basis. However, any device implanted in the body or in contact with flowing blood faces two critical challenges that can threaten the life of the patient the device is meant to help: blood clotting and bacterial infection.
Patient's question triggers important study about blood thinners
Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer.
Growth factors found in breast milk may protect against necrotizing enterocolitis
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal illness affecting up to 10% of premature infants, with a 30% mortality rate, and formula feeding has been identified as a risk factor for NEC.
Mechanical heart valves increase pregnancy risk
The fact that mechanical heart valves increase risks during and after pregnancy, has been confirmed by data from the ROPAC registry presented for the first time today in an ESC Congress Hot Line session by Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall of the registry's executive committee.
Best anticoagulants after orthopedic procedures depends on type of surgery
Current guidelines do not distinguish between aspirin and more potent blood thinners for protecting against blood clots in patients who undergo major orthopedic operations, leaving the decision up to individual clinicians.
More Heparin Current Events and Heparin News Articles